Mediwound (MDWD) Receives a Buy from Oppenheimer


In a report released yesterday, Jay Olson from Oppenheimer maintained a Buy rating on Mediwound (MDWD), with a price target of $15. The company’s shares closed yesterday at $4.97.

Olson wrote:

“We look forward to a catalyst-rich year for MDWD with a number of important events that we believe could result from the positive DETECT results for NexoBrid described in our Jan 22 report. These potential catalysts include: 1) a 1H19 pre-BLA meeting with FDA in order to define a streamlined pathway to US registration for NexoBrid BLA filing for burn wound debridement, 3) 2019 publication of DETECT results in journals along with presentations at medical meetings, 4) 1H19 initiation of a pivotal EscharEx Ph3 trial for debridement of chronic wounds, and 5) a March update on the potential for a strategic transaction. We maintain our optimistic view of MDWD with an Outperform rating and a $15 PT.”

According to TipRanks.com, Olson is ranked 0 out of 5 stars with an average return of -5.3% and a 40.5% success rate. Olson covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals Inc, Conatus Pharmaceuticals, and Enanta Pharmaceuticals.

Mediwound has an analyst consensus of Moderate Buy, with a price target consensus of $15.

See today’s analyst top recommended stocks >>

The company has a one-year high of $7.35 and a one-year low of $3.56. Currently, Mediwound has an average volume of 315.1K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

MediWound Ltd. is a biopharmaceutical company, which engages in the development, manufacture, and commercialization of novel products to address needs in the fields of severe burn; chronic and other hard-to-heal wounds; and connective tissue disorders.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts